These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27036684)

  • 1. Editorial Comment.
    Benson MC
    Urology; 2016 Apr; 90():147. PubMed ID: 27036684
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Kryvenko et al.: Prostate-specific Antigen Mass Density - A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution (Urology, 2016;90:141-147).
    Pishgar F
    Urology; 2016 Apr; 90():228-9. PubMed ID: 26809070
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply by the Authors.
    Kryvenko ON
    Urology; 2016 Apr; 90():229-30. PubMed ID: 26820119
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment from Dr Urakami to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Urakami S
    Int J Urol; 2014 Oct; 21(10):990-1. PubMed ID: 24909066
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment from Dr Simonato and Dr Romagnoli to impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy.
    Simonato A; Romagnoli A
    Int J Urol; 2014 Oct; 21(10):991. PubMed ID: 24931339
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.
    Bañez LL
    Urology; 2010 Nov; 76(5):e4. PubMed ID: 21056250
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific Antigen Mass Density--A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution.
    Kryvenko ON; Diaz M; Matoso A; Kates M; Cohen J; Swanson GP; Epstein JI
    Urology; 2016 Apr; 90():141-7. PubMed ID: 26773349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: The Impact of Obesity on the Predictive Accuracy of PSA in Men Undergoing Prostate Biopsy.
    Kaplan SA
    J Urol; 2015 Aug; 194(2):394-5. PubMed ID: 26195366
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment to association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Shimbo M
    Int J Urol; 2012 Aug; 19(8):747-8. PubMed ID: 22651131
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
    Froehner M
    Eur Urol; 2008 Aug; 54(2):368-9. PubMed ID: 18006213
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
    Stephan C; Jung K
    Eur Urol; 2008 Aug; 54(2):369-70. PubMed ID: 18006212
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.
    Yashi M
    Int J Urol; 2015 Jun; 22(6):561-2. PubMed ID: 25799888
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: current applications for prostate-specific antigen doubling time.
    Gallina A; Karakiewicz PI
    Eur Urol; 2008 Aug; 54(2):302. PubMed ID: 19209421
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment on: current applications for prostate-specific antigen doubling time.
    Semjonow A
    Eur Urol; 2008 Aug; 54(2):301. PubMed ID: 19209420
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: current applications for prostate-specific antigen doubling time.
    O'Brien MF
    Eur Urol; 2008 Aug; 54(2):300-1. PubMed ID: 19209419
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment.
    Loeb S
    Urology; 2014 Nov; 84(5):1167. PubMed ID: 25443924
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment.
    Gore JL
    Urology; 2011 Nov; 78(5):1113-4. PubMed ID: 22054381
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment.
    Ukimura O
    J Urol; 2014 Dec; 192(6):1648; discussion 1649. PubMed ID: 25194546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.